China's CStone ramps up yet another PD-1 clinical trial for solid tumors; Takeda faces profit decline on loss of Velcade exclusivity
→ Just how many PD-1/L1s does the world need to treat cancer?
With Regeneron and Sanofi within quick reach of their PDUFA date …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
